ethyl nicotinoylpyruvate | 92288-94-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl nicotinoylpyruvate
• 英文别名: 2,4-dioxo-4-pyridin-3-ylbutyric acid ethyl ester；ethyl 2,4-dioxo-4-(pyridin-3-yl)butanoate；Ethyl-nicotinoylpyruvat；2,4-Dioxo-4-pyrid-3-ylbuttersaeureethylester；2,4-Dioxo-4-[3]pyridyl-buttersaeure-aethylester；2,4-dioxo-4-[3]pyridyl-butyric acid ethyl ester；ethyl 4-(pyridin-3-yl)-2,4-dioxo-butyrate；ethyl 4-(3-pyridyl)-2,4-dioxo-butyrate；Ethyl 2,4-dioxo-4-pyridin-3-ylbutanoate
• CAS: 92288-94-3
• 化学式: C₁₁H₁₁NO₄
• mdl: MFCD03411540
• 分子量: 221.213
• InChiKey: ZADSMLIXHMTDJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  73.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  ethyl nicotinoylpyruvate 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以34%的产率得到5-(吡啶-3-基)-1H-吡唑-3-甲酸乙酯
  参考文献：
  名称：

  NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE

  摘要：

  本发明涉及作为硬脂酰辅酶A去饱和酶抑制剂的哌嗪衍生物。该发明还涉及制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。

  公开号：

  US20100160323A1
• 作为产物：
  描述：

  3-乙酰基吡啶 、 草酸二乙酯 在 sodium 作用下， 以 乙醇 、 乙醚 为溶剂， 反应 24.5h， 以48 g的产率得到ethyl nicotinoylpyruvate
  参考文献：
  名称：

  [EN] PYRAZOLYL-BASED CARBOXAMIDES AS CRAC INHIBITORS
  [FR] CARBOXAMIDES À BASE DE PYRAZOLYLE UTILISABLES COMME INHIBITEURS DE CRAC

  摘要：

  这项发明涉及以吡唑基为基础的羧酰胺化合物，其可用作ICRAC抑制剂，还涉及含有这些化合物的药物组合物，以及这些化合物在治疗和/或预防疾病和/或紊乱，特别是炎症性疾病和/或炎症性紊乱方面的用途。

  公开号：

  WO2015197188A1

文献信息

• Heterocyclic Compounds as Pesticides
  申请人：Bretschneider Thomas

  公开号：US20110212949A1

  公开（公告）日：2011-09-01

  The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.

  本申请涉及使用杂环化合物来控制动物害虫，包括节肢动物，特别是昆虫，此外还涉及新型杂环化合物及其制备方法。
• Thiazole derivatives and pharmaceutical composition comprising the same
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04649146A1

  公开（公告）日：1987-03-10

  The invention relates to novel pharmaceutical compounds for treatment for ulcer of the formula: ##STR1## wherein R.sup.1 is lower alkyl, carboxy, hydroxymethyl, halomethyl, lower alkylthiomethyl or hydroxyiminomethyl, R.sup.2 is hydrogen, hydroxy, lower alkyl, pyridyl, amino, lower alkylamino, pyridylamino or guanidino optionally substituted with dimethylaminomethylene, R.sup.3 is dihydroisoquinolyl which may be substituted with halogen, lower alkyl, lower alkoxy, carboxy, hydroxy, pyridyl, amino, lower alkylamino, pyridylamino or guanidino, Q is --CO--, and n is an integer of 0 or 1, and pharmaceutically acceptable salts thereof.

  该发明涉及一种用于治疗溃疡的新型药物化合物，其化学式为：##STR1## 其中R.sup.1为较低的烷基、羧基、羟甲基、卤代甲基、较低的烷基硫甲基或羟基亚甲基，R.sup.2为氢、羟基、较低的烷基、吡啶基、氨基、较低的烷基氨基、吡啶基氨基或胍基，可选择地取代二甲氨基亚甲基，R.sup.3为二氢异喹啉基，可取代卤素、较低的烷基、较低的烷氧基、羧基、羟基、吡啶基、氨基、较低的烷基氨基、吡啶基氨基或胍基，Q为--CO--，n为0或1，以及其药学上可接受的盐。
• Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives
  作者：Hiroyuki Tobinaga、Takayuki Kameyama、Kentarou Asahi、Tohru Horiguchi、Miho Oohara、Yoshiyuki Taoda、Kayoko Hata、Tsuyoshi Hasegawa、Yukio Tada、Naoko Kurihara、Yasuhiko Kanda、Shigenori Yagi、Maki Tomari、Yoshikazu Tanaka、Fumiyo Takahashi、Emiko Taniguchi、Yukio Takahara、Shinji Shimada、Chie Takeyama、Shoichi Yamamoto、Shunji Shinohara、Hiroyuki Kai

  DOI：10.1016/j.bmcl.2020.127636

  日期：2020.12

  The P2X3 receptor is an attractive target for the treatment of pain and chronic coughing, and thus P2X3 antagonists have been developed as new therapeutic drugs. We previously reported selective P2X3 receptor antagonists by derivatization of hit compound 1. As a result, we identified hit compound 3, the structure of which was similar to hit compound 1. On the basis of SAR studies of hit compound 1

  P2X3受体是治疗疼痛和慢性咳嗽的有吸引力的靶标，因此，P2X3拮抗剂已被开发为新的治疗药物。我们先前报道了命中化合物1衍生化的选择性P2X3受体拮抗剂。结果，我们确定了命中化合物3，其结构类似于命中化合物1。在对命中化合物1进行SAR研究的基础上，我们对命中化合物3进行了修饰，化合物42通过口服给药被确认具有镇痛作用。
• Thiazole derivatives, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04735957A1

  公开（公告）日：1988-04-05

  New thiazole derivatives of the formula: ##STR1## wherein R.sup.1 is lower alkyl, carboxy, a drivative of carboxy, hydroxymethyl, halomethyl, lower alkylthiomethyl, hydroxyiminomethyl or alkenyl which may be substituted with lower alkoxycarbonyl, pyridyl or cyano, R.sup.2 is hydrogen, hydroxy, lower alkyl, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkylN-acylamino, guanidino optionally substituted with dimethylaminomethylene, or ar(lower)alkylamino optionally substituted with lower alkoxy, R.sup.3 is lower alkyl, halo(lower)alkyl or N-containing unsaturated heterocyclic group which may be substituted with halogen, lower alkyl, lower alkoxy, carboxy, a derivative of carboxy, hydroxy, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkyl-N-acylamino, guanidino, N-oxide or ar(lower)alkylamino optionally substituted with lower alkoxy, Q is --CO--, and n is an integer of 0 or 1, provided that when both of R.sup.1 and R.sup.3 are lower alkyl then n is an integer of 1 and R.sup.2 is lower alkyl, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkyl-N-acylamino, guanidino optionally substituted with dimethylaminomethylene, or ar(lower)alkylamino optionally substituted with lower alkoxy, and when R.sup.1 is lower alkyl and R.sup.3 is halo(lower)alkyl then n is an integer of 1, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and pharmaceutically acceptable salts thereof are useful as cardiotonic agents and anti-ulcer agents.

  新的噻唑衍生物的化学式为：##STR1## 其中R.sup.1是较低的烷基，羧基，羧基衍生物，羟甲基，卤代甲基，较低的烷基硫甲基，羟基亚胺甲基或烯基，该烯基可以用较低的烷氧羰基，吡啶基或氰基取代，R.sup.2为氢，羟基，较低的烷基，吡啶基，氨基，较低的烷基氨基，吡啶基氨基，芳基氨基，酰基氨基，N-(较低)烷基N-酰基氨基，瓜二氨基可选地用二甲氨基甲基取代，或者是可选地用较低的烷氧基取代的ar(较低)烷基氨基，R.sup.3是较低的烷基，卤代(较低)烷基或含氮的不饱和杂环基，该基可以用卤代，较低的烷基，较低的烷氧基，羧基，羧基衍生物，羟基，吡啶基，氨基，较低的烷基氨基，吡啶基氨基，芳基氨基，酰基氨基，N-(较低)烷基-N-酰基氨基，瓜二氨基，N-氧化物或可选地用较低的烷氧基取代的ar(较低)烷基氨基取代，Q为--CO--，n为0或1的整数，但当R.sup.1和R.sup.3都是较低的烷基时，n为1的整数，而R.sup.2为较低的烷基，吡啶基，氨基，较低的烷基氨基，吡啶基氨基，芳基氨基，酰基氨基，N-(较低)烷基-N-酰基氨基，瓜二氨基可选地用二甲氨基甲基取代，或者是可选地用较低的烷氧基取代的ar(较低)烷基氨基，而当R.sup.1为较低的烷基且R.sup.3为卤代(较低)烷基时，n为1的整数，以及其药学上可接受的盐，以及其制备方法和包含其的制药组合物。这些衍生物及其药学上可接受的盐可用作心力衰竭药物和抗溃疡药物。
• Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0117082A2

  公开（公告）日：1984-08-29

  New thiazole derivatives for the formula: wherein R' is lower alkyl, carboxy, a derivative of carboxy, hydroxymethyl, halomethyl, lower alkylthiomethyl, hydroxyiminomethyl or alkenyl which may be substituted with lower alkoxycarbonyl, pyridyl or cyano. R2 is hydrogen, hydroxy, lower alkyl, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkylN-acylamino, guanidino optionally substituted with dimethylaminomethylene, or ar(lower) alkylamino optionally substituted with lower alkoxy, R3 is lower alkyl, halo(lower)alkyl or N-containing unsaturated heterocyclic group which may be substi- tued with halogen, lower alkyl, lower alkoxy, carboxy, a derivative of carboxy, hydroxy, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkyl-N-acylamino, guanidino, N-oxide or ar(lower)alkylamino optionally substituted with lower alkoxy, 0 is -CO-, and n is an integer of 0 or 1, provided that when both of R' and R3 are lower alkyl then n is an integer of 1 and R2 is lower alkyl, pyridyl, amino lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkyl-N-acylamino, guanidino optionally substituted with dimethylaminomethylene, or ar(lower) alkylamino optionally substituted with lower atkoxy, and when R1 is lower alkyl and R3 is halo(lower)alkyl then n is an integer of 1, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and pharmaceutically acceptable salts thereof are useful as cardiotonic agents and anti-ulcer agents.

  式中的新噻唑衍生物： 式中 R'是低级烷基、羧基、羧基的衍生物、羟甲基、卤甲基、低级烷硫基甲基、羟基亚氨基甲基或烯基，可被低级烷氧羰基、吡啶基或氰基取代。 R2 是氢、羟基、低级烷基、吡啶基、氨基、低级烷基氨基、吡啶基氨基、芳基氨基、酰基氨基、N-（低级）烷基-N-酰基氨基、任选被二甲氨基亚甲基取代的胍基，或任选被低级烷氧基取代的 ar（低级）烷基氨基、 R3 是低级烷基、卤代（低级）烷基或含 N 的不饱和杂环基团，可被卤素、低级烷基、低级烷氧基、羧基、羧基的衍生物、羟基、吡啶基、氨基、低级烷基氨基、吡啶氨基、芳基氨基、酰基氨基、N-（低级）烷基-N-酰基氨基、胍基、N-氧化物或可选择被低级烷氧基取代的 ar（低级）烷基氨基取代、 0 是-CO-，以及 n 是 0 或 1 的整数，条件是当 R' 和 R3 都是低级烷基时，n 是 1 的整数，且 R2 是低级烷基、吡啶基、氨基低级烷基氨基、吡啶基氨基、芳基氨基、酰基氨基、N-（低级）烷基-N-酰基氨基、任选被二甲氨基亚甲基取代的胍基、当 R1 为低级烷基，R3 为卤代（低级）烷基时，n 为 1 的整数。 这些衍生物及其药学上可接受的盐可用作强心剂和抗溃疡剂。